In a recent study, a novel CRISPR‐Cas9 system was used to knock out the cyclin‐dependent kinase 5 gene (CDK5), leading to the downregulation of PD‐L1 expression on tumor cells while promoting the population of cytotoxic effector cells in the TME.126. This evidence concerns the gene CDK5 and neoplasm.